T1	Participants 86 142	intermediate-grade and high-grade non-Hodgkin's lymphoma
T2	Participants 174 196	study of 464 patients.
T3	Participants 391 425	aggressive non-Hodgkin's lymphoma.
T4	Participants 834 917	Patients were younger than 55 years and had at least one adverse prognostic factor.
T5	Participants 1158 1170	464 patients